Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CSL Limited stock logo
CSLLY
CSL
$90.10
-0.7%
$92.06
$71.51
$105.11
$87.08B0.7335,519 shs30,771 shs
GSK plc stock logo
GSK
GSK
$40.88
-0.9%
$41.86
$33.33
$43.84
$85.47B0.643.45 million shs1.82 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$150.89
+0.9%
$173.11
$144.80
$201.92
$69.01B0.853.07 million shs3.64 million shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CSL Limited stock logo
CSLLY
CSL
-0.67%+2.43%-2.46%-6.36%-10.41%
GSK plc stock logo
GSK
GSK
-0.87%+3.23%-4.55%+5.25%+10.76%
Zoetis Inc. stock logo
ZTS
Zoetis
+0.89%-0.69%-10.08%-19.45%-12.79%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CSL Limited stock logo
CSLLY
CSL
0.4214 of 5 stars
0.03.01.70.01.10.01.3
GSK plc stock logo
GSK
GSK
2.9037 of 5 stars
0.03.03.30.03.10.02.5
Zoetis Inc. stock logo
ZTS
Zoetis
4.8154 of 5 stars
3.53.04.20.43.22.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CSL Limited stock logo
CSLLY
CSL
N/AN/AN/AN/A
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Zoetis Inc. stock logo
ZTS
Zoetis
3.00
Buy$218.0044.48% Upside

Current Analyst Ratings

Latest GSK, CSLLY, and ZTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$260.00 ➝ $230.00
4/16/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$220.00 ➝ $195.00
4/2/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$215.00 ➝ $195.00
3/4/2024
GSK plc stock logo
GSK
GSK
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
2/20/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$215.00 ➝ $220.00
2/14/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$255.00 ➝ $260.00
2/13/2024
GSK plc stock logo
GSK
GSK
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CSL Limited stock logo
CSLLY
CSL
$13.31B6.54$3.17 per share28.44$18.48 per share4.88
GSK plc stock logo
GSK
GSK
$30.33B2.79$5.22 per share7.83$7.74 per share5.28
Zoetis Inc. stock logo
ZTS
Zoetis
$8.54B8.08$6.66 per share22.67$10.87 per share13.88

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CSL Limited stock logo
CSLLY
CSL
$2.19BN/A0.0025.10N/AN/AN/AN/AN/A
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.589.231.4316.24%51.45%10.57%5/1/2024 (Confirmed)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.34B$5.0729.7623.612.2227.43%51.25%17.58%5/2/2024 (Confirmed)

Latest GSK, CSLLY, and ZTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$1.35N/A-$1.35N/AN/AN/A  
5/1/2024N/A
GSK plc stock logo
GSK
GSK
$0.95N/A-$0.95N/AN/AN/A
2/13/202412/31/2023
Zoetis Inc. stock logo
ZTS
Zoetis
$1.32$1.24-$0.08$1.34$2.19 billion$2.21 billion      
1/31/2024Q4 2023
GSK plc stock logo
GSK
GSK
$0.76$0.72-$0.04$1.23$9.79 billion$10.00 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CSL Limited stock logo
CSLLY
CSL
$1.091.21%N/AN/AN/A
GSK plc stock logo
GSK
GSK
$1.593.89%-18.20%52.82%1 Years
Zoetis Inc. stock logo
ZTS
Zoetis
$1.731.15%+23.31%34.12%12 Years

Latest GSK, CSLLY, and ZTS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/6/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Quarterly$0.43200.88%4/18/20244/19/20246/4/2024
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CSL Limited stock logo
CSLLY
CSL
N/AN/AN/A
GSK plc stock logo
GSK
GSK
1.19
0.88
0.62
Zoetis Inc. stock logo
ZTS
Zoetis
1.32
3.36
2.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CSL Limited stock logo
CSLLY
CSL
0.03%
GSK plc stock logo
GSK
GSK
15.74%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
CSL Limited stock logo
CSLLY
CSL
N/A
GSK plc stock logo
GSK
GSK
10.00%
Zoetis Inc. stock logo
ZTS
Zoetis
0.15%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CSL Limited stock logo
CSLLY
CSL
32,000966.51 millionN/ANot Optionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,100457.36 million456.67 millionOptionable

GSK, CSLLY, and ZTS Headlines

SourceHeadline
Zoetis (ZTS) Set to Announce Earnings on ThursdayZoetis (ZTS) Set to Announce Earnings on Thursday
americanbankingnews.com - April 25 at 1:28 AM
Bailard Inc. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)Bailard Inc. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 24 at 11:47 PM
Zoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets - Hagens BermanZoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets - Hagens Berman
markets.businessinsider.com - April 24 at 4:40 PM
Zoetis (NYSE:ZTS) Shares Up 0.8%Zoetis (NYSE:ZTS) Shares Up 0.8%
marketbeat.com - April 24 at 4:22 PM
Zoetis (NYSE:ZTS) Price Target Cut to $230.00 by Analysts at BarclaysZoetis (NYSE:ZTS) Price Target Cut to $230.00 by Analysts at Barclays
americanbankingnews.com - April 24 at 4:54 AM
GAMMA Investing LLC Takes Position in Zoetis Inc. (NYSE:ZTS)GAMMA Investing LLC Takes Position in Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 23 at 6:52 PM
ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities ...ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities ...
bakersfield.com - April 23 at 3:35 PM
Zoetis Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)Zoetis Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
markets.businessinsider.com - April 23 at 3:35 PM
Zoetis (ZTS) Fell After Reporting Mixed Fourth Quarter ResultsZoetis (ZTS) Fell After Reporting Mixed Fourth Quarter Results
finance.yahoo.com - April 23 at 3:35 PM
Zoetis (NYSE:ZTS) Shares Up 1.8%Zoetis (NYSE:ZTS) Shares Up 1.8%
marketbeat.com - April 23 at 2:58 PM
Zoetis (NYSE:ZTS) Price Target Cut to $230.00Zoetis (NYSE:ZTS) Price Target Cut to $230.00
marketbeat.com - April 23 at 11:58 AM
ROSEN, LEADING INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTSROSEN, LEADING INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS
markets.businessinsider.com - April 23 at 10:31 AM
Zoetis Inc. (NYSE:ZTS) Shares Acquired by New York State Common Retirement FundZoetis Inc. (NYSE:ZTS) Shares Acquired by New York State Common Retirement Fund
marketbeat.com - April 22 at 9:46 PM
Zoetis (ZTS) Stock Dips While Market Gains: Key FactsZoetis (ZTS) Stock Dips While Market Gains: Key Facts
zacks.com - April 22 at 7:21 PM
Zoetis (NYSE:ZTS) Trading Down 0.4%Zoetis (NYSE:ZTS) Trading Down 0.4%
marketbeat.com - April 22 at 2:33 PM
Zoetis (NYSE:ZTS) Shares Gap Up to $146.50Zoetis (NYSE:ZTS) Shares Gap Up to $146.50
marketbeat.com - April 22 at 12:49 PM
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the FirmIMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com - April 22 at 4:00 AM
Duality Advisers LP Buys 19,054 Shares of Zoetis Inc. (NYSE:ZTS)Duality Advisers LP Buys 19,054 Shares of Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 22 at 12:40 AM
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the FirmIMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com - April 21 at 6:00 AM
OVERSEA CHINESE BANKING Corp Ltd Buys 116,605 Shares of Zoetis Inc. (NYSE:ZTS)OVERSEA CHINESE BANKING Corp Ltd Buys 116,605 Shares of Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 20 at 3:58 PM
Roxanne Lagano Sells 923 Shares of Zoetis Inc. (NYSE:ZTS) StockRoxanne Lagano Sells 923 Shares of Zoetis Inc. (NYSE:ZTS) Stock
americanbankingnews.com - April 20 at 5:34 AM
Zoetis (NYSE:ZTS) Stock Price Down 2.9% Following Insider SellingZoetis (NYSE:ZTS) Stock Price Down 2.9% Following Insider Selling
americanbankingnews.com - April 20 at 1:42 AM
We Think Zoetis (NYSE:ZTS) Can Stay On Top Of Its DebtWe Think Zoetis (NYSE:ZTS) Can Stay On Top Of Its Debt
finance.yahoo.com - April 19 at 10:32 AM
Zoetis Inc. (NYSE:ZTS) Shares Acquired by Ninety One UK LtdZoetis Inc. (NYSE:ZTS) Shares Acquired by Ninety One UK Ltd
marketbeat.com - April 19 at 9:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CSL logo

CSL

OTCMKTS:CSLLY
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Zoetis logo

Zoetis

NYSE:ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.